tiprankstipranks
Trending News
More News >
Modalis Therapeutics Corporation (JP:4883)
:4883
Japanese Market

Modalis Therapeutics Corporation (4883) AI Stock Analysis

Compare
1 Followers

Top Page

JP

Modalis Therapeutics Corporation

(4883)

Rating:39Underperform
Price Target:
Modalis Therapeutics Corporation is currently facing severe financial difficulties characterized by zero revenue and increasing net losses. Although the balance sheet shows no debt and strong equity, the lack of operational performance improvement raises sustainability concerns. Technically, the stock is in a bearish trend with a negative market momentum, and the valuation remains unattractive with a negative P/E ratio. These factors combined result in a low overall stock score.

Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)

Modalis Therapeutics Corporation Business Overview & Revenue Model

Company DescriptionModalis Therapeutics Corporation (4883) is a biotechnology company focused on developing innovative gene therapies using its proprietary CRISPR-GNDM (Gene Modulation) technology. The firm operates primarily in the healthcare and biotechnology sectors, aiming to address unmet medical needs by targeting and modulating genetic expressions to treat a variety of genetic disorders. Its core services include the research and development of therapies designed to modulate gene expression without altering the underlying DNA sequence.
How the Company Makes MoneyModalis Therapeutics Corporation generates revenue through a combination of strategic partnerships, research collaborations, and licensing agreements. The company partners with pharmaceutical and biotechnology firms to co-develop gene therapies, sharing both the costs and potential profits. Additionally, Modalis may receive upfront payments, milestone payments, and royalties from its partners based on the development progress and commercial success of its therapeutic candidates. The company's revenue model relies heavily on its proprietary CRISPR-GNDM technology platform, which it licenses to other companies seeking to develop gene modulation therapies.

Modalis Therapeutics Corporation Financial Statement Overview

Summary
Modalis Therapeutics Corporation is facing significant financial challenges, with no revenue generation, increasing net losses, and reliance on financing to support cash flow. While the balance sheet remains strong with high equity and no debt, sustainability is a concern without improved revenue and operational performance.
Income Statement
10
Very Negative
The company has experienced a significant decline in revenue and profitability. Total revenue has dropped from 644 million in 2019 to zero in recent years, indicating a lack of sales. The net income remains negative with increasing losses, reflecting poor profitability and financial performance.
Balance Sheet
60
Neutral
The balance sheet shows strong stockholders' equity and no debt, resulting in a solid equity ratio. However, the lack of revenue generation and continuous net losses could impact equity sustainability in the long term, despite the current strong cash position.
Cash Flow
30
Negative
The cash flow statement indicates challenges in generating positive cash flow from operations, leading to negative free cash flow. The reliance on financing activities suggests potential sustainability issues without improving operational performance.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.0040.50M1.10M342.00M
Gross Profit0.00-731.00K-83.17M1.10M342.00M
EBITDA-2.15B-2.37B-2.58B-667.55M-381.96M
Net Income-1.32B-2.39B-2.70B-738.96M-448.41M
Balance Sheet
Total Assets3.69B2.03B3.13B6.07B6.28B
Cash, Cash Equivalents and Short-Term Investments3.58B1.88B2.93B4.94B5.42B
Total Debt0.00412.50M0.000.000.00
Total Liabilities143.47M645.50M188.60M519.92M70.16M
Stockholders Equity3.55B1.38B2.94B5.55B6.21B
Cash Flow
Free Cash Flow-1.43B-2.29B-2.09B-854.58M-1.21B
Operating Cash Flow-1.43B-2.25B-1.90B-747.47M-376.57M
Investing Cash Flow-188.00K-39.70M-185.72M171.56M-830.31M
Financing Cash Flow3.04B1.22B63.68M72.63M2.78B

Modalis Therapeutics Corporation Technical Analysis

Technical Analysis Sentiment
Negative
Last Price80.00
Price Trends
50DMA
80.66
Negative
100DMA
84.47
Negative
200DMA
97.59
Negative
Market Momentum
MACD
-0.17
Positive
RSI
39.86
Neutral
STOCH
7.72
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4883, the sentiment is Negative. The current price of 80 is below the 20-day moving average (MA) of 86.90, below the 50-day MA of 80.66, and below the 200-day MA of 97.59, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 39.86 is Neutral, neither overbought nor oversold. The STOCH value of 7.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4883.

Modalis Therapeutics Corporation Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
¥11.95B
109.03%98.53%
54
Neutral
¥13.13B
57.13%-66.39%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
48
Neutral
¥9.73B
14.41%27.42%
48
Neutral
¥167.94B-197.82%-3.32%
40
Underperform
¥9.53B-26.97%-30.46%39.41%
39
Underperform
¥6.15B
59.56%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4883
Modalis Therapeutics Corporation
80.00
10.00
14.29%
JP:4579
RaQualia Pharma Inc.
513.00
-81.00
-13.64%
JP:4583
Chiome Bioscience Inc.
141.00
7.00
5.22%
JP:4584
Kidswell Bio Corporation
224.00
88.00
64.71%
JP:4571
NanoCarrier Co., Ltd.
133.00
-47.00
-26.11%
JP:4592
SanBio Co
2,174.00
1,173.00
117.18%

Modalis Therapeutics Corporation Corporate Events

Modalis Completes New Share Issuance for Employee Remuneration
Apr 30, 2025

Modalis Therapeutics Corporation has completed the pay-in procedures for the issuance of 21,900 new common shares as part of a restricted-stock-based remuneration plan. This move, approved by the Board of Directors, aims to reward and incentivize directors, employees, and former employees, potentially enhancing stakeholder alignment and company performance.

Modalis Therapeutics Announces Terms for 16th Stock Option Program
Apr 14, 2025

Modalis Therapeutics Corporation announced the terms and conditions for its 16th stock option program, which includes issuing 8,800 share acquisition rights at an exercise price of 9,300 yen per unit. This move is aimed at incentivizing the company’s directors, employees, and subsidiary employees, potentially impacting the company’s market positioning and stakeholder engagement.

Modalis Therapeutics Announces New Share Issuance for Employee Incentives
Apr 14, 2025

Modalis Therapeutics Corporation has announced the issuance of 21,900 new shares as part of a restricted-stock-based remuneration plan. This initiative is designed to incentivize directors and employees by aligning their interests with the company’s long-term goals. The issuance is part of a broader strategy to enhance corporate value and involves a modest dilution of existing shares, deemed reasonable for the plan’s objectives.

Modalis Therapeutics Issues Stock Options to Boost Performance
Mar 27, 2025

Modalis Therapeutics Corporation announced the issuance of stock options to its employees and subsidiaries to enhance performance and secure skilled human resources. This move is expected to strengthen the company’s operational capabilities and improve its competitive positioning in the biotechnology sector.

Modalis Therapeutics Unveils FY2025 Business Plans with High Growth Potential
Mar 27, 2025

Modalis Therapeutics Corporation has outlined its business plans for FY2025, emphasizing its potential for high growth. The announcement highlights the company’s strategic focus on leveraging current market trends and regulatory conditions to enhance its operations and industry positioning, although it acknowledges the inherent risks and uncertainties in forward-looking statements.

Modalis Therapeutics Announces Change in Audit Firm
Feb 21, 2025

Modalis Therapeutics Corporation announced a change in its certified public accountants, with Alpha Audit Corporation set to replace KPMG AZSA LLC after the latter’s term ends on March 27, 2025. This decision, approved by the Audit and Supervisory Committee, aims to bring a fresh audit perspective, appropriate audit fees, and leverage Alpha Audit Corporation’s expertise and quality control, which may impact the company’s financial oversight and stakeholder confidence.

Modalis Therapeutics Expands Share Authorization for Enhanced Capital Strategy
Feb 21, 2025

Modalis Therapeutics Corporation announced a proposal to amend its Articles of Incorporation to increase the total number of authorized shares from 100,400,000 to 277,000,000. This strategic move aims to provide the company with more flexibility in capital raising and enhance its capital policy, potentially impacting its growth and market strategy.

Modalis Therapeutics Restructures Capital to Address Earnings Deficit
Feb 21, 2025

Modalis Therapeutics Corporation announced a strategic financial restructuring aimed at improving its financial health by covering a significant deficit in retained earnings. The company’s board has resolved to reduce its stated capital and capital reserves by equal amounts to bolster its capital surplus, which will then be used to offset the deficit, ensuring no impact on share numbers or net asset values.

Modalis Therapeutics Reports Reduced Losses Due to Lower R&D Expenses
Feb 13, 2025

Modalis Therapeutics Corporation reported a significant reduction in losses for the fiscal year ending December 31, 2024, compared to the previous year. The improvement in financial results is attributed to a decrease in research and development expenses, indicating a shift in the company’s cost management strategies.

Modalis Therapeutics Reports Foreign Exchange Gains
Feb 13, 2025

Modalis Therapeutics Corporation reported a non-operating income of 64 million yen due to foreign exchange gains for the fiscal year ending December 31, 2024. This financial update highlights the impact of currency fluctuation on the company’s foreign currency denominated assets, potentially affecting their overall financial performance.

Modalis Therapeutics Reports Reduced Losses in 2024 Financial Results
Feb 13, 2025

Modalis Therapeutics Corporation reported its consolidated financial results for the fiscal year ended December 31, 2024, showing a significant reduction in losses compared to the previous year. Despite the financial improvements, the company has not issued any earnings forecasts for 2025 due to uncertainties in the market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 23, 2025